“Atherogenic lipoproteins are really the issue behind clinical atherosclerotic vascular disease. … The data has just become so overwhelming.” —Tom Dayspring
“This is what it ultimately comes down to – and it’s the way you practice – you’ve got to individualize everything.” –Tom Dayspring
A companion post for the podcast episodes with Thomas Dayspring, M.D., FACP, FNLA (October 15-19, 2018).
In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.